BiomX (PHGE) AI Stock Analysis

• Market Cap: $3.42M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: N/A
• EPS Growth: 54.25%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.51
• Shares Outstanding: 1,526,640
• 10 Day Avg. Volume: 1,108,900
• 30 Day Avg. Volume: 1,322,820
• PEG Ratio: 0.04
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.38
• Enterprise Value/Market Cap: 9.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -115.67
• Enterprise Value/Ebitda: -1.13
• 1Y Price Target: $26.00
• Price Target Upside: 1060.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $2.00 ▼(-10.71% Downside)

The score is held down primarily by weak financial performance (minimal revenue, persistent losses and cash burn) and bearish technical trends (well below major moving averages with negative MACD). Offsetting factors are limited to modest balance-sheet leverage improvement and a cautiously positive clinical/regulatory outlook, though near-term liquidity needs and recent negative corporate developments keep the risk profile elevated.

Positive Factors

Regulatory clarity for BX011 (FDA feedback)

Concrete FDA guidance that defines a development pathway for BX011 materially reduces regulatory uncertainty and shortens the time and resources needed to progress to a potential Biologics License Application. This durable clarity supports prioritization of resources and increases program de-risking for the coming quarters.

Non-dilutive U.S. Defense funding supports BX011

~$40M of non-dilutive funding from Defense agencies provides substantive program financing that lessens near-term reliance on dilutive capital raises. Such strategic, non-dilutive support validates the technology's relevance to defense health priorities and sustainably underpins BX011 clinical advancement.

Improved balance-sheet leverage vs. prior year

A meaningful reduction in leverage and positive equity improve solvency resilience, lowering bankruptcy and covenant risk. This structurally enhances the company’s ability to negotiate with partners and creditors and provides more optionality to fund clinical programs over the medium term, assuming losses are managed.

Negative Factors

High cash burn and limited runway

Persistently negative operating and free cash flow with a cash balance funding operations only into Q1 2026 creates a structural financing necessity. This raises the likelihood of dilutive financings or partnership dependence, which can delay trials or force program prioritization, constraining long-term development plans.

Discontinuation of BX004 and subsidiary insolvency

Halting BX004 and an insolvency filing materially reduces pipeline breadth and clinical optionality, weakening future revenue and partnering potential. Loss of an advanced CF program and restructuring of a subsidiary are durable setbacks that may erode investor and partner confidence and increase execution risk for remaining programs.

Preferred Series Y financing raises dilution and governance risk

The preferred financing provides short-term liquidity but imposes expensive dividend obligations, near-term senior claims, and potential significant dilution via conversion and warrants. Board representation rights shift governance dynamics, creating lasting capital structure and control implications that may constrain strategic flexibility.

BiomX Business Overview & Revenue Model

Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

How the Company Makes Money

BiomX primarily makes money through research and development collaborations, grants, and potential future product sales. The company engages in partnerships with pharmaceutical and biotechnology companies to co-develop phage therapies, which can provide upfront payments, milestone payments, and royalties. Additionally, BiomX may receive funding from governmental or non-profit grants to support its research initiatives. As its products progress through clinical trials and potentially reach the market, revenue from sales of approved therapies will become a significant source of income.

BiomX Financial Statement Overview

Summary

BiomX faces significant financial challenges with persistent negative revenues and high operating losses. The balance sheet shows high leverage, and the cash flow statements indicate a reliance on external financing. Despite some improvements in net income and stockholders' equity, the company's overall financial health is strained.

Income Statement

BiomX has consistently reported negative revenues and gross profit over the years, indicating significant challenges in generating income. The company has also faced substantial net losses, although a notable improvement in net income was seen in 2024. The lack of revenue growth and negative margins, such as EBIT and EBITDA, highlight ongoing difficulties in achieving profitability.

Balance Sheet

The company's balance sheet shows high leverage, with a significant amount of total debt relative to equity, resulting in a concerning debt-to-equity ratio. However, the equity ratio indicates that a reasonable portion of the company's assets are financed by equity. Despite recent improvements in stockholders' equity, the overall financial stability remains a concern due to the high liabilities.

Cash Flow

BiomX's cash flow statements reflect ongoing negative free cash flow, indicating cash outflows from operations and investments. While there is a trend of securing financing to support cash needs, this reliance on external funding poses risks. The operating cash flow to net income ratio shows significant cash outflows relative to earnings, underscoring financial pressure.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-292.00K	-1.80M	-871.00K	0.00	0.00	0.00
EBITDA	-29.88M	-13.13M	-22.82M	-23.66M	-32.90M	-29.60M
Net Income	-37.38M	-17.73M	-26.17M	-28.32M	-36.23M	-30.09M
Balance Sheet
Total Assets	26.17M	43.23M	25.03M	45.53M	77.99M	70.36M
Cash, Cash Equivalents and Short-Term Investments	7.91M	17.81M	14.91M	33.33M	62.10M	56.33M
Total Debt	6.58M	9.58M	15.09M	19.36M	20.02M	5.89M
Total Liabilities	15.68M	19.09M	21.95M	24.49M	30.45M	12.89M
Stockholders Equity	10.49M	24.15M	3.08M	21.04M	47.53M	57.47M
Cash Flow
Free Cash Flow	-28.31M	-37.01M	-21.34M	-29.20M	-31.25M	-25.46M
Operating Cash Flow	-28.29M	-36.98M	-21.29M	-29.09M	-27.57M	-24.45M
Investing Cash Flow	106.00K	715.00K	1.95M	-2.11M	16.17M	-10.86M
Financing Cash Flow	11.54M	38.37M	2.90M	292.00K	37.28M	134.00K

BiomX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Negative. The current price of 2.24 is above the 20-day moving average (MA) of 2.07, below the 50-day MA of 4.68, and below the 200-day MA of 8.52, indicating a neutral trend. The MACD of -0.68 indicates Negative momentum. The RSI at 37.89 is Neutral, neither overbought nor oversold. The STOCH value of 80.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHGE.

BiomX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LPCN	51 Neutral	$41.81M	-7.41	-32.92%	―	-44.31%	-34.17%
PHGE	43 Neutral	$3.42M	-0.07	-154.50%	―	―	54.25%
CANF	41 Neutral	$5.68M	―	―	―	―	―
IMRN	38 Underperform	$7.88M	-1.40	-49.00%	―	47.17%	26.84%

BiomX Corporate Events

BiomX Subsidiary Terminates Maryland Facility Lease Agreement

On December 31, 2025, Adaptive Phage Therapeutics, LLC (APT), a wholly owned subsidiary of the Company, entered into a Seventh Amendment to its lease for premises in Gaithersburg, Maryland, resulting in the termination of the lease effective the same date. Under the settlement, APT agreed to a one-time payment of $800,000 and acknowledged the landlord’s draw on an existing letter of credit for $153,557.68, with the landlord agreeing, upon satisfaction of specified conditions, to release APT and the parent company from further obligations and liabilities under the lease, aside from limited surviving obligations, thereby resolving outstanding lease-related claims and closing out the company’s commitments at that facility.

The most recent analyst rating on (PHGE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Announces New Preferred Stock Financing and Warrants

On December 26, 2025, BiomX Inc. entered into a Securities Purchase Agreement with a single investor for a private placement of 3,300 shares of newly created Series Y Convertible Preferred Stock, with an aggregate stated value of $3.3 million, and accompanying warrants to purchase 3,300,000 shares of common stock, for expected gross proceeds of $3.0 million before fees. The Series Y Preferred Stock carries a 15% annual dividend payable in cash or stock, ranks senior to common stock and existing Series X preferred stock, has a one-year maturity, and is initially convertible at $2.00 per share, while the warrants are immediately exercisable at $2.00 per share for five years, with both instruments subject to price adjustments and a 19.99% beneficial ownership cap until stockholder approval is obtained. As part of the deal, the investor secured board representation rights tied to ownership thresholds, BiomX committed to seek stockholder approval within 60 days to permit issuance of more than 19.99% of its outstanding common shares, and it granted registration rights for resale of the underlying securities, signaling a significant equity financing that could meaningfully dilute existing shareholders but strengthens the company’s balance sheet and brings in an influential strategic investor; H.C. Wainwright & Co. acted as exclusive placement agent and will receive fees and additional warrants, and the transaction is expected to close on or about December 30, 2025, subject to customary conditions.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Discontinues Study and Files for Insolvency

On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b study due to resource constraints, which led to the decision to file for insolvency proceedings for its Israeli subsidiary, BiomX Ltd. The company is now evaluating strategic options while maintaining its BX011 program for diabetic foot infections.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Discontinues Phase 2b Trial for BX004

On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b clinical trial for BX004, a treatment for Cystic Fibrosis associated with chronic Pseudomonas aeruginosa infections, due to resource constraints. The company is now focusing on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, while also implementing cost-cutting measures and exploring strategic alternatives.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Updates on Phase 2b Study for BX004

On November 25, 2025, BiomX Inc. announced updates regarding its Phase 2b study of BX004 for Cystic Fibrosis treatment, which faced a clinical hold by the FDA due to concerns over a third-party nebulizer device. The company is actively working with the manufacturer to resolve these issues and anticipates resuming U.S. enrollment once resolved and financing is secured. Additionally, an independent Data Monitoring Committee recommended continuing the study with an adjusted dosing regimen after a safety review, with topline results expected in the second quarter of 2026, contingent on financial resources.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Approves Key Proposals at Annual Meeting

On October 16, 2025, BiomX Inc. held its Annual Meeting of Stockholders, where all proposed business items were approved. Stockholders elected three Class II directors to the board, authorized a potential reverse stock split, and ratified the selection of Kesselman & Kesselman as the independent public accounting firm for fiscal 2025. These decisions could impact the company’s governance and financial structure, potentially influencing its market positioning and operational strategies.

The most recent analyst rating on (PHGE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Faces FDA Questions on Nebulizer Device

On October 17, 2025, BiomX Inc. announced that the FDA had raised additional questions regarding the nebulizer device used in their Phase 2b study for the drug candidate BX004, aimed at treating Cystic Fibrosis. The company is continuing its study in Europe and plans to incorporate FDA feedback into future development plans, with topline results expected in early 2026.

The most recent analyst rating on (PHGE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.